ABSTRACT

**Purpose:** To determine the genetic background of sector retinitis pigmentosa (RP), natural history, in order to better inform patient counselling.

**Design:** Retrospective case series.

**Methods:** Review of clinical notes, retinal imaging including color fundus photography (CFP), fundus autofluorescence (FAF), and optical coherence tomography (OCT), electrophysiological assessment (ERG), and molecular genetic testing was performed in patients with sector RP from a single tertiary referral center.

**Main Outcome Measures:** Reporting demographic data, signs and symptoms, visual acuity, molecular genetics, ERG, FAF and OCT findings.

**Results:** Twenty-six molecularly confirmed patients from 23 different families were identified, harboring likely disease-causing variants in nine genes. The mode of inheritance was autosomal recessive (AR, n=6: **USH1C**, n=2; **MYO7A**, n=2; **CDH3**, n=1; **EYS**, n=1), X-linked (XL, n=4: **PRPS1**, n=1; **RPGR**, n=3), and autosomal dominant (AD, n=16: **IMPDH1**, n=3; **RP1**, n=3; **RHO**, n=10), with a mean age of disease onset of 38.5, 30.5 and 39.0 years respectively. Five of these genes have not previously been reported to cause sector RP (**PRPS1**, **MYO7A**, **EYS**, **IMPDH1**, and **RP1**). Inferior and nasal predilection was common across the different genotypes and patients tended to maintain good central vision. Progression on serial FAF was observed in **RPGR**, **MYO7A**, **CDH23**, **EYS**, **IMPDH1**, **RP1** and **RHO**-associated sector RP.

**Conclusions:** The genotypic spectrum of the disease is broader than previously reported. The provided longitudinal data will help to provide more accurate patient prognosis and counselling, as well as inform patients’ potential participation in the increasing numbers of trials of novel therapeutics and access to future treatments.
Sector Retinitis Pigmentosa: Extending the Molecular Genetics Basis and Elucidating the Natural History

Michalis Georgiou\textsuperscript{1,2}, Parampal S. Grewal\textsuperscript{2}, Akshay Narayan\textsuperscript{1}, Muath Alser\textsuperscript{1}, Naser Ali \textsuperscript{2}, Kaoru Fujinami\textsuperscript{1,2,3}, Andrew R. Webster\textsuperscript{1,2}, Michel Michaelides\textsuperscript{1,2}

\textsuperscript{1} UCL Institute of Ophthalmology, University College London, London, UK
\textsuperscript{2} Moorfields Eye Hospital, London, UK
\textsuperscript{3} Laboratory of Visual Physiology, Division of Vision Research, National Institute of Sensory Organs, National Hospital Organization Tokyo Medical Center, Tokyo, Japan; Department of Ophthalmology, Keio University School of Medicine, Tokyo, Japan.

Corresponding author:
Michel Michaelides,
UCL Institute of Ophthalmology,
11-43 Bath Street, London, EC1V 9EL, UK.
E-mail: michel.michaelides@ucl.ac.uk
Tel. no: 004420 7608 6864

Number of Figures: 6

Supplementary Materials: 3 (2 tables, 1 figure)

Running (Short) Title: Sector Retinitis Pigmentosa

Supplemental Material available at AJO.com.
Keywords: fundus autofluorescence, FAF, optical coherence tomography, OCT, retina, retinitis pigmentosa, sector, sectorial, sectoral, RP, inherited retinal disease, dystrophy, genetics
INTRODUCTION

Retinitis pigmentosa (RP) is a heterogeneous group of inherited retinal disorders (IRD), characterized by nyctalopia, visual field (VF) defects, and progressive retinal degeneration.\(^1\) RP can also exist in syndromic forms, such as Usher syndrome and Bardet-Biedl syndrome.\(^2\) Sector RP and pericentral RP are atypical variants of RP.\(^3,4\)

Sector RP was first reported in 1937, with limited subsequent reports in the literature, despite representing a distinct phenotype. It is characterized by typical clinical features of RP limited to one or two fundus quadrants.\(^5\) It tends to affect inferior and nasal quadrants with corresponding superior VF defects.\(^6\) Sector RP has a favourable visual prognosis compared to generalized RP, having been reported that 82% retain a visual acuity (VA) of 20/40 or better.\(^7\) Autosomal dominant (AD), autosomal recessive (AR) and X-linked (XL) modes of inheritance have been reported. There are six previously reported disease-causing genes: rhodopsin (AD, RHO, OMIM 180380, n=70 cases),\(^4,6,8-17\) usherin (AR, USH1C, OMIM 605242, n=2),\(^2\) cadherin 23 (AR, CDH23, OMIM 605516, n=1),\(^18\) retinol dehydrogenase 5 (AR, RDH5, OMIM 601617, n=1),\(^19\) arrestin (AR, SAG, OMIM 181031, n=1),\(^20\) and more recently RP GTPase regulator gene (X-linked, RPGR, OMIM 312610, n=2).\(^4,21\) All the previously reported sector RP causing variants are summarized in Supplementary Table 1. Currently there are ongoing efforts for the development and approval of novel therapeutic options for RPGR-RP and RHO-RP.\(^22,23\)

There are limited publications on sector RP, in particular longitudinal natural history studies are limited to case reports. Herein, we report the largest series and first longitudinal study in molecularly confirmed patients with sector RP. While sector RP is believed to be a mild condition compared to generalized RP, there is need for more robust data to advise on prognosis. This is particularly true in the molecular era and with the development of novel therapeutics.

The purpose of this study is therefore to investigate genetic and phenotypic variability in a large cohort of molecularly confirmed patients with sector RP seen in a tertiary center, as well as to investigate disease natural history and provide valuable information that can better inform patient counselling and prognostication.
METHODS

Patient Identification
All correspondence on the electronic clinical database (OpenEyes) at Moorfields Eye Hospital (MEH), London, UK was searched for the key words: “sector”, “sectorial”, and “sectoral”. The clinical notes of all the identified patients were reviewed to confirm the diagnosis of sector RP. All patients with a confirmed clinical diagnosis were seen in retinal genetics clinics and evaluated by experienced specialists (ARW and MM). The patients were identified in the MEH Inherited Eye Disease database for molecular confirmation. Patients were included in this database after obtaining informed consent. This study adhered to the tenets of the Declaration of Helsinki and was approved by the MEH ethics committee.

Assessments
Medical notes and clinical images were reviewed, including dilated fundoscopy, VA recording, electrophysiological assessment (ERG), retinal imaging including color fundus photography (CFP; Optos, California and TopCon), optical coherence tomography (OCT, Heidelberg Spectralis) and fundus autofluorescence (FAF, Heidelberg Spectralis and Optos California). The age of disease onset was defined as the age of the first disease related symptom(s). Full-field and pattern electroretinography were performed using gold foil electrodes to incorporate the International Society for Clinical Electrophysiology of Vision standards (ISCEV) in nine patients.

Retinal Imaging
The retina was divided into four halves, with the center at the fovea: the superior-inferior and nasal-temporal meridians, defined the nasal and temporal retina, and the superior and inferior retina respectively (Supplementary Figure 1). FAF imaging (55 degrees) and CFP were used to evaluate the extent of retinal involvement. The presence of a perimacular ring of increased signal on FAF was also noted. Macular involvement was also investigated, using all available modalities. Interocular symmetry was evaluated qualitatively, taking into account the topology of the affected quadrants and the extent of degeneration. Eyes with different affected quadrants were defined as asymmetric.

Foveal total retinal thickness (FTRT) and outer nuclear layer (ONL) thickness were calculated at baseline and last follow-up. All measurements were made by a single examiner using the digital calipers built into the software (Heidelberg Eye Explorer; Heidelberg Engineering), and a 1-pixel:1-μm display with maximum magnification. FTRT was measured as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE). ONL thickness was measured as the distance between the ILM and the external limiting membrane (ELM), or the distance between the outer plexiform layer (OPL) and the ELM, for patients without and with foveal hypoplasia respectively.

Statistical Methods
The statistical analysis was carried out using SPSS Statistics (Chicago, IL, USA). Significance for all statistical tests was set at $P < 0.05$. The Shapiro-Wilk test was used to test for normality for all variables.
RESULTS

Patient Characteristics
Twenty-six molecularly confirmed patients were identified, from 23 pedigrees (as noted with Pedigree number on Table 1), harboring likely disease-causing variants in nine genes. The modes of inheritance were X-linked (XL, n=4: \textit{PRPS1}, n=1; \textit{RPGR}, n=3), autosomal recessive (AR, n=6: \textit{USH1C}, n=2; \textit{MYO7A}, n=2; \textit{CDH23}, n=1; \textit{EYS}, n=1), and autosomal dominant (AD, n=16: \textit{IMPDH1}, n=3; \textit{RP1}, n=3; \textit{RHO}, n=10). Five of these genes have not previously been reported to cause sector RP (\textit{PRPS1}, \textit{MYO7A}, \textit{EYS}, \textit{IMPDH1}, and \textit{RP1}). The molecular genetics, sex, and family history, of all patients are presented in Table 1. The clinical presentation including the age of disease onset, of each genotype are presented individually below. The two siblings with \textit{USH1C} variants and sector RP were previously described in detail by Saihan et al,\textsuperscript{2} and were excluded from OCT, FAF, and further individual analysis.

Visual Acuity and Disease Symmetry
VA was available for 24 of the 26 patients. From the 24 patients, two had reduced VA in one eye, unrelated to retinal degeneration (P1: left eye - closed angle glaucoma and cataract, P19: right eye - amblyopia), and were excluded from VA interocular comparison. The mean VA at baseline examination (mean age: 42.8, range: 18.3-76.1) for the right and left eyes was 0.035 and 0.061 LogMAR respectively. VA was similar between right and left eyes ($P=0.203$, $t=-1.31$, df=21). Twenty patients had longitudinal VA assessment, with a mean follow-up of 10.6 years (range: 2.3-36.1 years). Final mean VA was 0.06 and 0.10 LogMAR for right and left eyes respectively. VA was statistically significantly worse at follow-up ($P=0.007$, $t=-3.05$, df=19). Figure 1 presents the VA for all patients over time, with genotype details.

In all patients evaluated for interocular symmetry (n=25), the disease was symmetric between eyes in 23 patients (92%), in terms of the available CFP, OCT and FAF. Figure 2 presents FAF examples of interocular symmetry for all genotypes, with the exception of \textit{PRPS1}. While \textit{PRPS1} is known to cause asymmetric disease in females,\textsuperscript{24} imaging data was only available from the right eye (due to dense left cataract and prior left angle closure) precluding interocular comparison (Figure 3A). The two other patients (P3-\textit{RPGR} and P17-\textit{RHO}) with intraocular difference in presentation were only noted on wide-field imaging (Figure 3B-C).

OCT Quantitative and Qualitative assessment
OCT imaging was performed at least once in 18 patients (mean age: 46 years, range: 18-90 years). Mean foveal thickness was 156 $\mu$m and 152 $\mu$m for right and left eyes respectively. Mean ONL thickness was 124 $\mu$m and 120 $\mu$m for right and left eyes respectively. Previously reported mean ± SD from unaffected controls for ONL thickness are 112.9 ± 15.2 (right eye) and 112.1 ± 13.9 $\mu$m (left eye).\textsuperscript{25} One patient (5.6%, P4) had macular involvement, with loss of the macular ellipsoid zone (Figure 4B).

Thirteen patients had serial OCT assessment with a mean final follow-up of 5.6 years (range: 4.4-8.1 years). Mean foveal thickness was 154 $\mu$m and 152 $\mu$m for right and left eyes respectively. Mean ONL thickness was 117 $\mu$m and 112 $\mu$m for right and left eyes respectively. Examples of OCT interocular symmetry and disease progression
are presented in Figure 4. Cystoid macular edema (CME) was observed in four patients (P2-RPGR (Figure 4A), P11-IMPDH1, P13-IMPDH1 (Figure 4D) and P26-RHO (Figure 4F)), with one having XL (P2) and three AD (P11, P13, P26) inheritance mode. Three patients had epiretinal membrane (P2 (Figure 4A), P12 and P14). One patient had focal vitreomacular traction (VMT; P13, Stage 1 (Figure 4D)).

**Disease Localization and Evidence of Progression**

FAF imaging was used for localization of the disease and investigation of structural progression, due to the peripheral nature of the disease and the wider field of view compared to OCT. Eighteen patients had 55 degree FAF imaging (mean age: 46 years old, range: 18.3-70.4 years old). Fifteen patients (83.3%) had peripapillary atrophic changes (Figures 5 A-D and F-J). The three patients without peripapillary changes were P7, P9 (Figure 5E) and P16, with MYO7A, CDH23 and RP1 genotypes respectively. A common finding was a hyperautofluorescent rim, bordering areas of affected and healthy retina (n=13, 72.2%, Figures 2 and 5). A peri-foveal ring of increased signal was present in two subjects (11.1%, P14-RP1 (Figure 5H) and P26-RHO (Figure 5J)). Both of these patients had hyperautofluorescent rings and rims. Foveal involvement was observed only in one subject (P4-RPGR, Figure 5C). Disease localization was noted: i) nasal (n=1, 5.6%, P2-RPGR carrier, Figure 5A), ii) inferior (n=6, 33.3%), iii) inferior and nasal (n=9, 50%), and iv) inferior, temporal and nasal (n=2, 11.2%, P13-IMPDH1 and P14-RP1). Disease localization for each individual patient is presented in Supplementary Table 2.

Sixteen patients had available follow-up imaging (mean follow-up time 5 years, range: 1-9.1 years). Seven of the 16 patients (43.8%), showed changes in the FAF signal. Figure 5 presents all six patients with evidence of progression; the changes were peripheral and small in area, and most likely of limited clinical significance. Only one patient showed extension of the disease to the superior retina (P14-RP1), having a more “typical” RP presentation, with mid-peripheral changes in all quadrants (Figure 5H). The mean follow-up of the patients with structural changes was 5.6 years (range 4-7.8 years).

**X-linked Sector RP**

**PRPS1 (n=1)**

The patient (P1) was diagnosed at age 45 and presented with reduced vision. Vision in the left eye was perception of light and without clear visual axis, due to previous angle closure glaucoma. Inferior atrophy with pigmentary changes were documented on fundoscopy. The VA in the right eye was 0.27 LogMAR at 76 years of age, and only mildly deteriorated to 0.48 LogMAR at 91 years of age. While no FAF imaging was available for disease localization; CFP documented the disease in the inferior retina (Figure 3A).

**RPGR (n=3)**

Three patients harbored RPGR variants in ORF15. One female carrier (P2) had an age of disease onset at 32 years, presenting with increased difficulty with night vision. VA was 0.24 and 0.18 LogMAR at 35 years of age and remained relatively stable at 0.18 and 0.3 LogMAR after 16 years of follow-up, for right and left eye respectively. The two
affected males had an earlier age of onset, at age 4 years (P3) and 10 years (P4), with the later diagnosed at asymptomatic screening by an optometrist and the former having reduced color vision. VA for P3 at 18 years of age was 0.18 LogMAR in both eyes. P4 at 37 years of age had a baseline VA of 0.18 LogMAR in both eyes, and over 13.5 years of follow-up deteriorated to 0.92 and 0.52 LogMAR in the right and left eye respectively. Greater disease progression and VA deterioration was observed in the right eye due to foveal involvement (Figure 5C). All three patients showed involvement of the inferior and nasal retina on FAF (Figure 5A-C). The affected female also had a tapetal-like reflex, a common finding among *RPGR*-carriers, visible both on fundoscopy and FAF (Figure 2A). P2 had ERG testing at age 34 years, showing generalized retinal dysfunction, affecting both the cone and the rod system, with macular involvement. Rod specific ERG was precluded by blink artefact. P3 had ERG testing at age 29 years, showing generalized retinal dysfunction, affecting more the rod than the cone system, with paracentral macular involvement. Interestingly the affected male cousin of P3, has a symmetrical, non-sectorial phenotype of cone-rod dystrophy, despite harboring the same *RPGR* variant.

**Autosomal Recessive Sector RP**

*MYO7A* (n=2)

Patients P7 and P8, from two independent pedigrees and both severely hearing impaired, were referred for evaluation of pigmentary changes in the inferior retina after routine optometry assessment (Figure 6A-B), without any associated visual complaint, at age 53 and 45 years old respectively. Superior field defects were noted in both patients. VA for P7, was 0 and -0.08 LogMAR at age 57, and 0.0 and 0.16 LogMAR at age 62 years, for right and left eye respectively. VA for P8 was 0.0 LogMAR for both eyes at age 46, and 0.12 and 0.0 LogMAR for right and left eye after 15 years of follow-up. P7 had normal pattern and full-field ERGs at age 58 years, and P8 had normal pattern ERG, and mildly subnormal full-field ERG, with normal peak times, at 44 years of age.

*CDH23* (n=1)

P9 had Usher syndrome Type 1 and he was referred at 18 years of age for evaluation (Figure 6C). He had bilateral cochlear implants. VA was 0.0 and -0.08 LogMAR at 18 years of age, and 0.04 and 0.06 after six years of follow-up for the right and left eye respectively. Previous ERG testing at 7 years of age showed normal responses from both eyes, which deteriorated after 8 years of follow-up both for the rod and to a lesser extent the cone system.

*EYS* (n=1)

P10 when 54 years old was noted by her optometrist to have bilateral supero-temporal VF defects, and was referred for evaluation. VA was -0.14 and 0.0 LogMAR at 55 years of age, and 0.0 and 0.18 after four years of follow-up in the right and the left eye respectively. Vessel attenuation, pale discs and inferior RPE granularity were observed on fundoscopy and remained relatively stable during follow-up; visible on FAF (Figure 5F). ERG at 56 years of age, showed a reduction in rod and cone amplitudes, with no peak-time shift.
Autosomal Dominant Sector RP

**IMPDH1 (n=3)**
The mean age of presentation was 56.3 years old (range 52.1 - 70.4 years). P11 and P13 were asymptomatic and incidentally noted to have retinal changes. P12 presented with peripheral field constriction and difficulty focusing. The mean presenting VA was 0.06 logMAR (range 0.00 – 0.18 logMAR). Patient P12 had superior visual field constriction to 20 degrees. P11 was the only patient who had an ERG, which demonstrated generalised retinal dysfunction, affecting the rod more than cone systems. None of the patients had foveal involvement or progression on FAF (Figure 2G and 5G).

**RP1 (n=3)**
The mean age of presentation was 33.1 years-old (range 26.0 – 41.1 years). The mean presenting VA was 0.06 logMAR (range 0.00 – 0.18 logMAR). On ERG, P14 had generalized dysfunction of the rod system and P16 had generalised retinal dysfunction of both rod and cone systems. Two of the patients showed evidence of mild progression on FAF (Figure 5H-I).

**RHO (n=10)**
Patients with RHO variants had a mean age of presentation of 52.2 years-old (range 28.6 – 61.7 years). Four patients presented with nyctalopia, five presented with peripheral visual symptoms, and the final patient was asymptomatic. The mean presenting VA was 0.03 logMAR (range 0.00 - 0.24 logMAR). None of the patients had foveal involvement, and only one had evidence of mild progression on FAF (Figure 5J).
DISCUSSION
Herein, we investigated the genetic and phenotypic variation in the largest cohort of molecularly confirmed patients with sector RP in the literature. We identified nine genes as causative for the disease, of which five were not previously implicated (PRPS1, MYO7A, EYS, IMPDH1, and RP1). We provided data for disease natural history and information that can help inform patient counselling and prognosis for each individual genotype.

Sector RP has a favourable visual prognosis compared to “typical” RP. It has been reported that 82% of patients retain a VA of 0.3 LogMAR or better (n=17, not molecularly confirmed). In our cohort, 24 patients (24/26, 83.3%) had VA better than 0.3 LogMAR (Figure 1). Coussa et al. recently reported that those with sector RP due to RHO (n=9) retain relatively good central vision (better than 0.18 LogMAR). In agreement with the aforementioned study, 87.5% (7/8) of our patients with RHO variants had VA equal or better than 0.18 LogMAR. In our cohort, relative structural and functional stability was observed across all genotypes during follow-up (Figure 1 and Figure 5). We recently reported 105 affected families with RHO-associated disease in our genetic database, in the current report we associate 8 of them with sector RP (7.6%). A predisposition for inferior and/or nasal retinal involvement has been reported for sector RP due to RHO, and that was also observed in all the cases in the current report. There are on-going human clinical trials of antisense oligonucleotide therapy and hydroxychloroquine (NCT04123626 and NCT04120883 respectively) for patients harboring the RHO variant P23H. This variant has also been reported in sector RP. None of our 8 families harboured P23H; with this variant being common in the USA. Overall, our data support that most patients with sector RP, albeit with a degree of variability depending on the genotype, can be advised of a good prognosis, with serial monitoring for progression with wide-field imaging and for secondary complications with OCT (e.g. CME, Figure 5F).

RPGR-associated sector RP appears to have distinct features from other genotypes and a worse prognosis. Two patients are reported in the literature with RPGR variants and sectoral disease (Table 1); one patient had impaired central vision with asymmetry between the eyes (0.48 and 1.3 LogMAR), and the other was described as having cone-rod dystrophy (rather than RP=rod-cone dystrophy) and sectoral disease, presenting also with impaired central vision. RPGR patients (n=3) tended to have worse VA for their age in the cohort (Figure 1). Asymmetry in VA, was noted in P4 over the follow-up (0.4 LogMAR interocular difference), and can be attributed to foveal involvement, where small structural changes can have a more dramatic effect on VA. Both of the aforementioned patients in the literature (reported recently from two independent centers), and our P3 had a small deletion leading to a frameshift at the same location (c.3092). It should also be highlighted that P2 was an RPGR carrier and to the best of our knowledge is the first reported carrier with sector RP (Figure 2A). In all the reported patients with RPGR variants, the changes are primarily nasal and peripapillary (Figure 2A-C). Trials of gene augmentation therapy are already underway for RPGR-associated RP (NCT03252847, NCT03116113, and NCT03316560).

Usher syndrome is genetically and phenotypically heterogeneous, and with the current report we further extend the phenotypic spectrum of the retinal manifestations of
the causative genes. *USH1C* causes Usher type 1C (OMIM 276904), and has previously been associated with sector RP (P5 and P6 in the current study).\(^2\) *MYO7A* and *CDH23* are causes of USH1B (OMIM 276900) and USH1D (OMIM 601027) respectively. P7 and P8 with *MYO7A*, had severe congenital hearing loss, could articulate and wore hearing aids, suggesting some useful hearing, which is not typical in USH1B. In keeping with the milder hearing deficit, retinal disease was also mild and limited to the inferior retina. Both patients have minimal ERG abnormality, in contrast to the usually undetectable responses in *MYO7A*-associated USH1B (88.6%).\(^3\) Three of the four variants identified in P7 and P8, are missense changes and may represent hypomorphic alleles, thereby allowing residual cochlear function and sector RP. P9 with *CDH23* variants was compound heterozygous for a null and a missense variant. Non-syndromic deafness is associated with *CDH23* missense variants that are presumed to be hypomorphic alleles with sufficient residual activity for retinal function, but not for auditory cochlear function. In contrast, null *CDH23*, or a combination of a null allele and a missense in a compound heterozygote, cause USH1D.\(^3\) Our case is the second case reported in the literature where the combination of a null and missense variant leads to deafness and sector RP (i.e. mild retinal manifestations).\(^1\)

*RP1* encodes a microtubule-associated protein which is thought to be retin-specific and sequence variants are known to cause AD and AR RP.\(^31,32\) Notably, AD *RP1* RP has a relatively mild phenotype, with variants clustered in the large terminal exon 4, as was the case in our patients (P14 – P16). Previously reported variants are usually truncating,\(^33\) as was also the case in our patients. Variants in other exons can cause a more severe phenotype including early-onset retinal degeneration, but only when homozygous.\(^32\) Of note, two of our three patients with *RP1* showed some progression on serial FAF; however, none demonstrated foveal involvement. *IMPDH1* encodes inosine-5-prime-monophosphate dehydrogenase which is responsible for guanine nucleotide biosynthesis. It has been reported to cause AD RP and rarely Leber congenital amaurosis.\(^34\) *IMPDH1-RP* has been attributed to protein misfolding as opposed to reduced enzymatic activity.\(^35\) Sector RP due to *RP1* and *IMPDH1* represent a milder phenotype, with no definite genotype-phenotype association evident, suggesting other modifying molecular or environmental factors.

Light exposure has been implicated given the inferior retinal predilection of sector RP. Light deprivation reduces retinal degeneration in related RP animal models.\(^36\) Animal models exhibiting rhodopsin glycosylation deficiency are vulnerable to light related retinal degeneration.\(^37,38\) This may be clinically relevant, as occupationally related high sunlight exposure may lead to a more severe phenotype, potentially (at least in part) explaining the commonly observed intrafamilial phenotypic variability in *RHO-RP*.\(^39\) While the underlying molecular mechanism remains unclear, it is interesting that the inferior predilection was common among the 9 causative genes identified herein. Speculation of a common / down-stream mechanism of light-induced damage is possible. Gradients of gene expression in the retina that are not normally clinically manifest might also predispose the retinal quadrants differently. Given the current evidence, it is reasonable to also advise patients with sector RP to use protection and minimize light exposure.

Our series highlights that the genotypic spectrum is broader. However, as a single tertiary referral center it is difficult to draw conclusions for disease prevalence
within the general population, as well as about the prevalence of each gene in patients with sector RP, since mild cases or cases with dominant inheritance may lack molecular confirmation. Our study was retrospective, and as a result not all the data were available for all the patients. Further evaluation and quantification of the ERG parameters, and use of wide-field imaging longitudinally will be of value to monitor disease progression.

Herein we presented the largest cohort of molecularly confirmed patients with sector RP. The genotypic spectrum of the disease is broader than previously reported, with 5 novel genes causing sector RP identified. The provided longitudinal data will be valuable to better inform patient prognosis and counselling.
Acknowledgments and Disclosures

Funding

Supported by grants from the National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, Onassis Foundation, Leventis Foundation, The Wellcome Trust (099173/Z/12/Z), Moorfields Eye Hospital Special Trustees, Moorfields Eye Charity, Retina UK, Fight for Sight UK, and the Foundation Fighting Blindness (USA).

Financial Disclosures:

Michalis Georgiou and Michel Michaelides consult for MeiraGTx. The following authors have no financial disclosures: PSG, AN, MA, NA, KF, ARW.

Conflict of Interest:

No conflict of interest exist for any of the authors.

Authorship:

All authors attest that they meet the current ICMJE criteria for Authorship.

Acknowledgements:

None
REFERENCES


[FIGURE LEGENDS]

Figure 1: Visual Acuity Graphical Representation
Twenty four patients had available visual acuity (VA) data, with 20 patients being longitudinally assessed, with a mean follow-up of 10.6 years (range: 2.3-36.1 years). The graph represents VA at baseline and follow-up (where available), over age. Each genotype is presented with a different marker.

Figure 2: Disease Symmetry
Fundus autofluorescence imaging of the right and left eyes of ten patients (A-J), with sector retinitis pigmentosa. Disease was symmetric in all the presented cases, with the exception P3 (B). The age and the genotype of each individual is noted in the figure.

Figure 3: Examples of Disease Asymmetry
(A) PRPS1 is known to cause asymmetric disease in females, multimodal imaging data were only available from the right eye precluding interocular comparison. Left: Color Fundus photograph (CFP), Right: near-infrared imaging of the right eye with the white line marking the location of the transfoveal optical coherence tomography (OCT) scan presented below. (B) and (C) examples of interocular asymmetry. (B) P3 has more advanced disease nasally in the left eye (white arrow heads), which are better visualised with fundus autofluorescence imaging (second line). (C) CFPs of P17, with more advanced disease temporal to the fovea in the right eye (white arrow heads).

Figure 4: Optical Coherence Tomography (OCT) in Sector Retinitis Pigmentosa
(A-F) Transfoveal horizontal OCT scans of six patients with sector RP, of both eyes at baseline and follow-up. Genotype, age at baseline and follow-up time are noted in the figure. (A, C and E) Patients had no foveal involvement and stable disease. (B) P4 had foveal involvement, with no evidence of progression over follow-up. (D) P13 had vitreomacular traction (VMT; P13, Stage 1 in the right eye). (A) P2, (D) P13 and (F) P26, had varying degrees of cystoid macular edema; with (D) likely being secondary to traction.
R: right eye, L: left eye, y: years

Figure 5: Disease Progression
Fundus autofluorescence imaging of right or left eyes of ten patients (A-J), with sector retinitis pigmentosa, at baseline and follow-up. The genotype of the patient and the age at baseline and follow-up is noted in the figure. The white arrow heads mark the areas of progression in seven patients. Any noted progression was small in area/extent with most likely no/limited clinical impact.
yo: years old

Figure 6: Wide-field imaging in Sector Retinitis Pigmentosa (RP)
On the left, color fundus photographs of the right and left eyes of five patients with sector RP, and on the right, corresponding fundus autofluorescence (FAF) images. Genotype and age of each patients are presented in the figure. For cases (A-C) disease
is extending well below the arcades and it is thereby not possible to fully assess with conventional 55 degree FAF (Figure 2).
<table>
<thead>
<tr>
<th>Patient ID</th>
<th>Pedigree ID</th>
<th>Genetics</th>
<th>Genes</th>
<th>Sex</th>
<th>Family History</th>
<th>Nucleotide change</th>
<th>Amino acid change/effect</th>
<th>Variant 1</th>
<th>Nucleotide change</th>
<th>Amino acid change/effect</th>
<th>Variant 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>X-linked Sector Retinitis Pigmentosa</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P1</td>
<td>20175</td>
<td>35460</td>
<td><strong>PRPS1</strong></td>
<td>F</td>
<td>Y</td>
<td>c.47C&gt;T</td>
<td>p.Ser16Phe</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P2</td>
<td>1737</td>
<td>21404</td>
<td><strong>RPGR</strong></td>
<td>F</td>
<td>Y</td>
<td>c.1239_1243delAGAGA</td>
<td>p.(Glu414Glyfs*37)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P3</td>
<td>5345</td>
<td>31560</td>
<td><strong>RPGR</strong></td>
<td>M</td>
<td>N</td>
<td>c.3092delA</td>
<td>p.(Glu1031Glyfs*58)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P4</td>
<td>4297</td>
<td>26063</td>
<td><strong>RPGR</strong></td>
<td>M</td>
<td>Y</td>
<td>c.485_486delTT</td>
<td>p.Phe162Tyrfs*4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Autosomal Recessive Sector Retinitis Pigmentosa</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P5</td>
<td>16975</td>
<td>26022</td>
<td><strong>USH1C</strong></td>
<td>M</td>
<td>Y</td>
<td>c.308 G&gt;A</td>
<td>p.Arg103His</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P6</td>
<td>16975</td>
<td>30346</td>
<td><strong>USH1C</strong></td>
<td>F</td>
<td>Y</td>
<td>c.308 G&gt;A</td>
<td>p.Arg103His</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P7</td>
<td>20699</td>
<td>31899</td>
<td><strong>MYO7A</strong></td>
<td>M</td>
<td>N</td>
<td>c.3476G&gt;T</td>
<td>p.Gly1159Val</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P8</td>
<td>19131</td>
<td>29686</td>
<td><strong>MYO7A</strong></td>
<td>M</td>
<td>N</td>
<td>c.22dupG</td>
<td>p.Asp8Glyfs*34</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P9</td>
<td>21894</td>
<td>33976</td>
<td><strong>CDH23</strong></td>
<td>M</td>
<td>N</td>
<td>c.5237G&gt;A</td>
<td>p.Arg1746Gln</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P10</td>
<td>22692</td>
<td>34950</td>
<td><strong>EYS</strong></td>
<td>F</td>
<td>Y</td>
<td>c.6794delC</td>
<td>p.Pro2265Glnfs*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P11</td>
<td>20700</td>
<td>31900</td>
<td><strong>IMPDH1</strong></td>
<td>M</td>
<td>Y</td>
<td>c.1074+6_1074+7delGCinsT</td>
<td>p.?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P12</td>
<td>18732</td>
<td>28954</td>
<td><strong>IMPDH1</strong></td>
<td>F</td>
<td>Y</td>
<td>c.968A&gt;G</td>
<td>p.Lys323Arg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P13</td>
<td>24034</td>
<td>37043</td>
<td><strong>IMPDH1</strong></td>
<td>F</td>
<td>N</td>
<td>c.1603A&gt;G</td>
<td>p.Lys535Glu</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P14</td>
<td>3650</td>
<td>2322</td>
<td><strong>RP1</strong></td>
<td>F</td>
<td>y</td>
<td>c.2172_2185del</td>
<td>p.Ile725Argfs*6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P15</td>
<td>21079</td>
<td>32583</td>
<td><strong>RP1</strong></td>
<td>F</td>
<td>y</td>
<td>c.2029C&gt;T</td>
<td>p.Arg667*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P16</td>
<td>18591</td>
<td>28719</td>
<td><strong>RP1</strong></td>
<td>F</td>
<td>y</td>
<td>c.2206dupA</td>
<td>p.Thr736Asnfs*4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P17</td>
<td>16765</td>
<td>23876</td>
<td><strong>RHO</strong></td>
<td>F</td>
<td>y</td>
<td>c.165C&gt;A</td>
<td>p.Asn55Lys</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P18</td>
<td>2482</td>
<td>1535</td>
<td><strong>RHO</strong></td>
<td>M</td>
<td>Y</td>
<td>c.937-1G&gt;T</td>
<td>p.?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P19</td>
<td>1379</td>
<td>4976</td>
<td><strong>RHO</strong></td>
<td>F</td>
<td>y</td>
<td>c.410G&gt;T</td>
<td>p.Met39Arg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P20</td>
<td>1379</td>
<td>22517</td>
<td><strong>RHO</strong></td>
<td>F</td>
<td>y</td>
<td>c.410G&gt;T</td>
<td>p.Met39Arg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P21</td>
<td>3509</td>
<td>21686</td>
<td><strong>RHO</strong></td>
<td>F</td>
<td>y</td>
<td>c.568G&gt;A</td>
<td>p.Asp190Asn</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P22</td>
<td>3509</td>
<td>9533</td>
<td><strong>RHO</strong></td>
<td>M</td>
<td>y</td>
<td>c.568G&gt;A</td>
<td>p.Asp190Asn</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 1: Demographics and Genetics
<p>| | | | | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>P24</td>
<td>3492</td>
<td>10471</td>
<td>RHO</td>
<td>F</td>
<td>N</td>
<td>N</td>
<td>c.467C&gt;G</td>
<td>p.Thr58Arg</td>
</tr>
<tr>
<td>P26</td>
<td>19172</td>
<td>29744</td>
<td>RHO</td>
<td>M</td>
<td>y</td>
<td>N</td>
<td>c.116T&gt;G</td>
<td>p.Met39Arg</td>
</tr>
</tbody>
</table>

Transcript ID: PRPS1 (NM_002764.4); RPGR (NM_001034853.2); USH1C (NM_153676.4); MYO7A (NM_000260); CDH23 (NM_022124.6); EYS (NM_001142800.1); IMPDH1 (NM_000883.4); RP1(NM_006269.2); RHO (NM_000539.3)
Highlights

- This is the largest series and longitudinal study in sector retinitis pigmentosa.
- The genotypic spectrum of the disease is broader than previously reported.
- The provided longitudinal data provide more accurate patient prognosis and counselling.
- The study inform patients’ potential participation in the increasing numbers of trials of novel therapeutics and access to future treatments.